Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine

• Published in: Annals of hematology Vol. 99; no. 3; pp. 527 - 537
• Main Authors: Martín, Iván, Navarro, Blanca, Serrano, Alicia, Villamón, Eva, Calabuig, Marisa, Solano, Carlos, Chaves, Felipe Javier, Yagüe, Nuria, Orts, Maribel, Amat, Paula, Fuentes, Azahara, Seda, Enrique, García, Francisca, Hernández-Boluda, Juan Carlos, Tormo, Mar
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2020; Springer Nature B.V
• Subjects: Aged; Aged, 80 and over; Azacitidine - administration & dosage; Chromosome Deletion; Chromosomes, Human, Pair 7 - genetics; Chromosomes, Human, Pair 7 - metabolism; Cyclin-Dependent Kinase Inhibitor p15 - genetics; Cyclin-Dependent Kinase Inhibitor p15 - metabolism; Cytogenetics; Disease-Free Survival; DNA Methylation - drug effects; DNA, Neoplasm - genetics; DNA, Neoplasm - metabolism; Female; GTPase-Activating Proteins - genetics; GTPase-Activating Proteins - metabolism; Hematology; Humans; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - metabolism; Leukemia, Myeloid, Acute - mortality; Male; Medicine; Medicine & Public Health; Middle Aged; Mutation; Myelodysplastic syndromes; Myelodysplastic Syndromes - drug therapy; Myelodysplastic Syndromes - genetics; Myelodysplastic Syndromes - metabolism; Myelodysplastic Syndromes - mortality; Oncology; Original Article; Promoter Regions, Genetic; Survival Rate; Tumor Suppressor Proteins - genetics; Tumor Suppressor Proteins - metabolism; Promoter methylation; Gene mutations; Azacitidine; Platelet doubling; Acute myeloid leukemia; Myelodysplastic syndromes

Azacitidine (AZA) is a DNA hypomethylation agent administered in myeloid neoplasms; however, there is still a lack of established predictors of response. We studied 113 patients with myelodysplastic syndromes ( n  = 85) or acute myeloid leukemia ( n  = 28) who received AZA to assess the predictive v...